Physician profile
Angele C Wright
NPI 1366123556
$2,447.67
in general payments reported to CMS, 2019-2025
21 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $291 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $384.39 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $364.28 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $324.03 | 2024-2025 | |
| Astellas Pharma US INC | $242.74 | 2024-2025 | Veozah |
| Lilly USA, LLC | $182.69 | 2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $154.11 | 2024-2025 | |
| Exact Sciences Corporation | $139.49 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $130.26 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $94.17 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $58.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.99 | 2024-2025 | Jardiance |
| Tris Pharma INC | $47.52 | 2024-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $45.32 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $45.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.49 | 2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.93 | 2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $26.11 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.75 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $21.26 | 2025 | Rexulti |
| Dexcom, INC. | $20.78 | 2025 | Dexcom G6 Transmitter |
| Resmed Corp | $14.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angele Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.